SLU-PP-332
Also called ERR agonist; "exercise mimetic"
An experimental small molecule, not a peptide, that activates estrogen-related receptors (ERRs) involved in energy use. It improved endurance in mice; it has not been shown to replace exercise or cause weight loss in people.
Overview
What it is
A synthetic compound that activates all three ERR subtypes (alpha, beta, gamma), most strongly ERR-alpha. Despite the name, ERRs do not bind estrogen, so it is not an estrogen product.
How it works
ERRs control genes for mitochondrial and aerobic energy use. Activating them produced an exercise-like gene response in mouse muscle.
What the research shows
A 2023 study found better endurance in mice; several authors held stock in a company developing ERR drugs. A 2024 study found weight and metabolic improvements in obese mice but not in normal-diet mice. A 2026 paper described SLU-PP-332 as not orally bioavailable and studied a different compound, SLU-PP-915, as the oral version.
Studied for
- Exercise endurancemice
- Metabolic syndrome in obese miceanimal
Safety and regulatory status
Safety and side effects
No reliable human side-effect rate, interaction data or long-term safety information exists. Unknown risk is not the same as confirmed safety.
Regulatory status
Not approved by the FDA for any use.
Mixing and dosing reference
Reference information only. Read before using this section.
SLU-PP-332 (5 mg Vial) Dosage Protocol
- Vial
- 5 mg SLU-PP-332
- Add diluent
- 3 mL
- Concentration
- 1.67 mg/mL
- 1 unit (U-100)
- 16.67 mcg in 0.01 mL
- Route
- Subcutaneous
- How often
- Twice per day, reflecting published murine regimens.
Murine-Equivalent Protocol
| Phase | Daily Dose (mcg) | Per-Injection Dose (mcg) | Units per Injection (mL) |
|---|---|---|---|
| Weeks 1–2 | 1250 mcg | 625 mcg | 37.5 units (0.375 mL) |
| Weeks 3–8 | 2500 mcg | 1250 mcg | 75 units (0.75 mL) |
How to mix
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Dosing details
- Murine-equivalent dosing framework.
- Initial Phase (Weeks 1–2): 1250 mcg daily (625 mcg per injection, twice daily).
- Maintenance Phase (Weeks 3–8): 2500 mcg daily (1250 mcg per injection, twice daily).
- Frequency: Twice per day, reflecting published murine regimens.
- Route: Intraperitoneal (as studied in preclinical models).
- Timing: Consistent intervals between administrations.
Storage
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
- Allow vials to reach room temperature before opening to reduce condensation.
- Protect from light during storage and handling.
Important notes
- Research compound considerations.
- No human data: SLU-PP-332 has not been tested in human subjects; all evidence is from murine models.
- Use new sterile syringes for each administration; dispose in a sharps container.
- Rotate injection sites to reduce local irritation.
- Document administration times, doses, and any observations.
- This compound is for research purposes only - not for human consumption.
Protocol source: PeptideDosages.com
Common questions
Is SLU-PP-332 a peptide?
No. It is a small-molecule chemical.
Is it a SARM or steroid?
No. It acts on ERRs, not androgen receptors.
Does it work as a pill?
Researchers describe it as lacking oral bioavailability; the oral research compound is a different molecule (SLU-PP-915).
Can it replace exercise?
No. It reproduces some exercise-related signals in mice, not the whole-body benefits of exercise.
Related in Metabolic Health
Sources and further reading (5)
- Billon C, et al. Synthetic ERR agonist enhances exercise capacity. ACS Chem Biol, 2023.
- Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. JPET, 2024.
- Billon C, et al. Orally active ERR agonist SLU-PP-915. JPET, 2026.
- Plaza-Florido A, et al. Exercise pills cannot mimic the exercise milieu. Trends Endocrinol Metab, 2026.
- Source summary: PeptideDosages.com research overview (rewritten for NVO).